Orion Corporation Announces Significant Milestone Payment
Orion Corporation has made an exciting announcement regarding a milestone payment of EUR 180 million linked to the sales of its notable drug, Nubeqa®. This payment is set to be recognized in the final quarter of 2025, which has prompted the company to reassess its financial outlook for the year.
Updated Financial Projections for 2025
With the new milestone payment on the horizon, Orion Corporation has revised its full-year projections for both net sales and operating profit. The updated estimation for net sales now ranges between EUR 1,820 million and EUR 1,900 million. Meanwhile, the operating profit is expected to be in the range of EUR 590 million to EUR 670 million, reflecting the positive impact of the anticipated milestone.
Previous Estimates Adjusted
Just a short while ago, on 28 October 2025, Orion had forecasted its net sales for 2025 to range from EUR 1,640 million to EUR 1,720 million, with an operating profit estimated between EUR 410 million and EUR 490 million. The recent adjustments highlight the company's strong market positioning and growth potential.
Key Leadership at Orion Corporation
At the helm of Orion Corporation are its executives, President and CEO Liisa Hurme and CFO René Lindell, who are instrumental in steering the company towards its financial goals. Their leadership is vital as Orion continues to expand its reach and effectiveness in the pharmaceutical market.
Investor Relations Contact
For inquiries regarding investments or corporate updates, Tuukka Hirvonen, the Head of Investor Relations, is available at +358 10 426 2721. Engaging with investor relations is crucial for stakeholders looking to understand the evolving dynamics of the company.
About Orion Corporation
Orion is an esteemed Nordic pharmaceutical company that has dedicated over a century to promoting health and well-being globally. Their commitment to developing, manufacturing, and marketing both human and veterinary pharmaceuticals is backed by a deep portfolio of proprietary and generic medicines, as well as consumer healthcare products. Orion's primary research areas include oncology and pain management, with proprietary products specifically designed to treat a variety of conditions such as cancer and respiratory diseases.
Recent Performance
In the previous year, Orion reported net sales of EUR 1,542 million, showcasing the company's effectiveness and commitment to quality. With approximately 3,700 professionals working diligently around the globe, Orion continues striving to enhance well-being through its innovative products and services. Both A and B shares of Orion are actively traded on Nasdaq Helsinki, reflecting the company's robust market presence and investor interest.
Frequently Asked Questions
What is the significance of the EUR 180 million milestone payment?
The EUR 180 million milestone payment represents a substantial financial boost for Orion Corporation, linked to the sales of its drug Nubeqa®.
How has Orion Corporation updated its financial outlook for 2025?
Orion Corporation has raised its estimates for net sales to between EUR 1,820 million and EUR 1,900 million and operating profit to EUR 590 million to EUR 670 million.
What were the previous financial estimates from Orion Corporation?
Previously, Orion estimated net sales for 2025 to range from EUR 1,640 million to EUR 1,720 million and operating profit between EUR 410 million and EUR 490 million.
Who are the key executives at Orion Corporation?
Liisa Hurme serves as the President and CEO while René Lindell is the CFO, leading the company through its strategic initiatives.
How can I contact Orion Corporation for investor relations?
For any inquiries related to investments, Tuukka Hirvonen, Head of Investor Relations, can be reached at +358 10 426 2721.
